Stalled Gilead leukemia drug ignites former top scientist’s new company

Norbert Bischofberger liked what he saw from a Gilead cancer drug at the time, but it just wasn’t effective enough at the time. Now as CEO of a biotech startup, he has more information — and he has the drug.